-
1
-
-
0343337185
-
Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide-methoxychlor: Interactions of methoxychlor metabolites with the constitutive androstane receptor system
-
Blizard D, Sueyoshi T, Negishi M, Dehal SS, and Kupfer D (2001) Mechanism of induction of cytochrome P450 enzymes by the proestrogenic endocrine disruptor pesticide-methoxychlor: interactions of methoxychlor metabolites with the constitutive androstane receptor system. Drug Metab Dispos 29:781-785.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 781-785
-
-
Blizard, D.1
Sueyoshi, T.2
Negishi, M.3
Dehal, S.S.4
Kupfer, D.5
-
2
-
-
0030430033
-
Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes
-
Bourrié M, Meunier V, Berger Y, and Fabre G (1996) Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J Pharmacol Exp Ther 277:321-332.
-
(1996)
J Pharmacol Exp Ther
, vol.277
, pp. 321-332
-
-
Bourrié, M.1
Meunier, V.2
Berger, Y.3
Fabre, G.4
-
3
-
-
0027504510
-
Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta-1,4-diene-3,17-dione)
-
Buzzetti F, Di Salle E, Longo A, and Briatico G (1993) Synthesis and aromatase inhibition by potential metabolites of exemestane (6-methylenandrosta- 1,4-diene-3,17-dione). Steroids 58: 527-532.
-
(1993)
Steroids
, vol.58
, pp. 527-532
-
-
Buzzetti, F.1
Di Salle, E.2
Longo, A.3
Briatico, G.4
-
4
-
-
0038128342
-
Constitutive androstane receptor and pregnane X receptor gene expression in human liver: Interindividual variability and correlation with CYP2B6 mRNA levels
-
Chang TK, Bandiera SM, and Chen J (2003) Constitutive androstane receptor and pregnane X receptor gene expression in human liver: interindividual variability and correlation with CYP2B6 mRNA levels. Drug Metab Dispos 31:7-10.
-
(2003)
Drug Metab Dispos
, vol.31
, pp. 7-10
-
-
Chang, T.K.1
Bandiera, S.M.2
Chen, J.3
-
5
-
-
0034049569
-
Exemestane: A review of its use in postmenopausal women with advanced breast cancer
-
Clemett D and Lamb HM (2000) Exemestane: a review of its use in postmenopausal women with advanced breast cancer. Drugs 59:1279-1296.
-
(2000)
Drugs
, vol.59
, pp. 1279-1296
-
-
Clemett, D.1
Lamb, H.M.2
-
6
-
-
10744223655
-
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
-
DOI 10.1056/NEJMoa040331
-
Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081-1092. (Pubitemid 38298988)
-
(2004)
New England Journal of Medicine
, vol.350
, Issue.11
, pp. 1081-1092
-
-
Coombes, R.C.1
Hall, E.2
Gibson, L.J.3
Paridaens, R.4
Jassem, J.5
Delozier, T.6
Jones, S.E.7
Alvarez, I.8
Bertelli, G.9
Ortmann, O.10
Coates, A.S.11
Bajetta, E.12
Dodwell, D.13
Coleman, R.E.14
Fallowfield, L.J.15
Mickiewicz, E.16
Andersen, J.17
Lonning, P.E.18
Cocconi, G.19
Stewart, A.20
Stuart, N.21
Snowdon, C.F.22
Carpentieri, M.23
Massimini, G.24
Bliss, J.M.25
more..
-
7
-
-
33846545851
-
Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial
-
Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, et al. (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559-570.
-
(2007)
Lancet
, vol.369
, pp. 559-570
-
-
Coombes, R.C.1
Kilburn, L.S.2
Snowdon, C.F.3
Paridaens, R.4
Coleman, R.E.5
Jones, S.E.6
Jassem, J.7
Van De Velde, C.J.8
Delozier, T.9
Alvarez, I.10
-
8
-
-
67649158224
-
A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma
-
Corona G, Elia C, Casetta B, Diana C, Rosalen S, Bari M, and Toffoli G (2009) A liquid chromatography-tandem mass spectrometry method for the simultaneous determination of exemestane and its metabolite 17-dihydroexemestane in human plasma. J Mass Spectrom 44:920-928.
-
(2009)
J Mass Spectrom
, vol.44
, pp. 920-928
-
-
Corona, G.1
Elia, C.2
Casetta, B.3
Diana, C.4
Rosalen, S.5
Bari, M.6
Toffoli, G.7
-
9
-
-
0027429541
-
Relationship between genotype and function of the human CYP1A1 gene
-
Cosma G, Crofts F, Taioli E, Toniolo P, and Garte S (1993) Relationship between genotype and function of the human CYP1A1 gene. J Toxicol Environ Health 40:309-316.
-
(1993)
J Toxicol Environ Health
, vol.40
, pp. 309-316
-
-
Cosma, G.1
Crofts, F.2
Taioli, E.3
Toniolo, P.4
Garte, S.5
-
10
-
-
33645518818
-
Role of polymorphic human cytochrome P450 enzymes in estrone oxidation
-
Cribb AE, Knight MJ, Dryer D, Guernsey J, Hender K, Tesch M, and Saleh TM (2006) Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol Biomarkers Prev 15:551-558.
-
(2006)
Cancer Epidemiol Biomarkers Prev
, vol.15
, pp. 551-558
-
-
Cribb, A.E.1
Knight, M.J.2
Dryer, D.3
Guernsey, J.4
Hender, K.5
Tesch, M.6
Saleh, T.M.7
-
11
-
-
0028557312
-
Functional significance of different human CYP1A1 genotypes
-
Crofts F, Taioli E, Trachman J, Cosma GN, Currie D, Toniolo P, and Garte SJ (1994) Functional significance of different human CYP1A1 genotypes. Carcinogenesis 15:2961-2963.
-
(1994)
Carcinogenesis
, vol.15
, pp. 2961-2963
-
-
Crofts, F.1
Taioli, E.2
Trachman, J.3
Cosma, G.N.4
Currie, D.5
Toniolo, P.6
Garte, S.J.7
-
12
-
-
43149086393
-
Chemoprevention of breast cancer
-
Cuzick J (2008) Chemoprevention of breast cancer. Breast Cancer 15:10-16.
-
(2008)
Breast Cancer
, vol.15
, pp. 10-16
-
-
Cuzick, J.1
-
13
-
-
0032160463
-
Further characterization of the expression in liver and catalytic activity of CYP2B6
-
Ekins S, Vandenbranden M, Ring BJ, Gillespie JS, Yang TJ, Gelboin HV, and Wrighton SA (1998) Further characterization of the expression in liver and catalytic activity of CYP2B6. J Pharmacol Exp Ther 286:1253-1259.
-
(1998)
J Pharmacol Exp Ther
, vol.286
, pp. 1253-1259
-
-
Ekins, S.1
Vandenbranden, M.2
Ring, B.J.3
Gillespie, J.S.4
Yang, T.J.5
Gelboin, H.V.6
Wrighton, S.A.7
-
14
-
-
0031792505
-
Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties
-
Hellmold H, Rylander T, Magnusson M, Reihnér E, Warner M, and Gustafsson JA (1998) Characterization of cytochrome P450 enzymes in human breast tissue from reduction mammaplasties. J Clin Endocrinol Metab 83:886-895.
-
(1998)
J Clin Endocrinol Metab
, vol.83
, pp. 886-895
-
-
Hellmold, H.1
Rylander, T.2
Magnusson, M.3
Reihnér, E.4
Warner, M.5
Gustafsson, J.A.6
-
15
-
-
0035150854
-
Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: Potential drug interactions with bupropion
-
Hesse LM, von Moltke LL, Shader RI, and Greenblatt DJ (2001) Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos 29:100-102.
-
(2001)
Drug Metab Dispos
, vol.29
, pp. 100-102
-
-
Hesse, L.M.1
Von Moltke, L.L.2
Shader, R.I.3
Greenblatt, D.J.4
-
16
-
-
2542446523
-
The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women
-
Jannuzzo MG, Poggesi I, Spinelli R, Rocchetti M, Cicioni P, and Buchan P (2004) The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women. Cancer Chemother Pharmacol 53:475-481.
-
(2004)
Cancer Chemother Pharmacol
, vol.53
, pp. 475-481
-
-
Jannuzzo, M.G.1
Poggesi, I.2
Spinelli, R.3
Rocchetti, M.4
Cicioni, P.5
Buchan, P.6
-
17
-
-
4344673341
-
Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone
-
Kamdem LK, Meineke I, Koch I, Zanger UM, Brockmöller J, and Wojnowski L (2004) Limited contribution of CYP3A5 to the hepatic 6β-hydroxylation of testosterone. Naunyn Schmiedebergs Arch Pharmacol 370:71-77.
-
(2004)
Naunyn Schmiedebergs Arch Pharmacol
, vol.370
, pp. 71-77
-
-
Kamdem, L.K.1
Meineke, I.2
Koch, I.3
Zanger, U.M.4
Brockmöller, J.5
Wojnowski, L.6
-
18
-
-
0028063131
-
CYP3A gene expression in human gut epithelium
-
Kolars JC, Lown KS, Schmiedlin-Ren P, Ghosh M, Fang C, Wrighton SA, Merion RM, and Watkins PB (1994) CYP3A gene expression in human gut epithelium. Pharmacogenetics 4:247-259.
-
(1994)
Pharmacogenetics
, vol.4
, pp. 247-259
-
-
Kolars, J.C.1
Lown, K.S.2
Schmiedlin-Ren, P.3
Ghosh, M.4
Fang, C.5
Wrighton, S.A.6
Merion, R.M.7
Watkins, P.B.8
-
19
-
-
0034948077
-
Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver
-
Lang T, Klein K, Fischer J, Nüssler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, and Zanger UM (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
-
(2001)
Pharmacogenetics
, vol.11
, pp. 399-415
-
-
Lang, T.1
Klein, K.2
Fischer, J.3
Nüssler, A.K.4
Neuhaus, P.5
Hofmann, U.6
Eichelbaum, M.7
Schwab, M.8
Zanger, U.M.9
-
20
-
-
0346101833
-
Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males
-
Mauras N, Lima J, Patel D, Rini A, di Salle E, Kwok A, and Lippe B (2003) Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males. J Clin Endocrinol Metab 88:5951-5956.
-
(2003)
J Clin Endocrinol Metab
, vol.88
, pp. 5951-5956
-
-
Mauras, N.1
Lima, J.2
Patel, D.3
Rini, A.4
Di Salle, E.5
Kwok, A.6
Lippe, B.7
-
21
-
-
0028204887
-
The molecular basis of genetic polymorphisms of drug metabolism
-
Meyer UA (1994) The molecular basis of genetic polymorphisms of drug metabolism. J Pharm Pharmacol 46 (Suppl 1):409-415.
-
(1994)
J Pharm Pharmacol
, vol.46
, Issue.SUPPL 1
, pp. 409-415
-
-
Meyer, U.A.1
-
22
-
-
41149083559
-
Tamoxifen, hot flashes and recurrence in breast cancer
-
Mortimer JE, Flatt SW, Parker BA, Gold EB, Wasserman L, Natarajan L, Pierce JP, and WHEL Study Group (2008) Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108:421-426.
-
(2008)
Breast Cancer Res Treat
, vol.108
, pp. 421-426
-
-
Mortimer, J.E.1
Flatt, S.W.2
Parker, B.A.3
Gold, E.B.4
Wasserman, L.5
Natarajan, L.6
Pierce, J.P.7
Study Group, W.8
-
23
-
-
85013917085
-
Genetic polymorphism of human cytochrome p450 involved in drug metabolism
-
Nagata K and Yamazoe Y (2002) Genetic polymorphism of human cytochrome p450 involved in drug metabolism. Drug Metab Pharmacokinet 17:167-189.
-
(2002)
Drug Metab Pharmacokinet
, vol.17
, pp. 167-189
-
-
Nagata, K.1
Yamazoe, Y.2
-
24
-
-
0031748287
-
Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones
-
Niwa T, Yabusaki Y, Honma K, Matsuo N, Tatsuta K, Ishibashi F, and Katagiri M (1998) Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica 28:539-547.
-
(1998)
Xenobiotica
, vol.28
, pp. 539-547
-
-
Niwa, T.1
Yabusaki, Y.2
Honma, K.3
Matsuo, N.4
Tatsuta, K.5
Ishibashi, F.6
Katagiri, M.7
-
25
-
-
0342980835
-
Novel metabolic pathway of estrone and 17betaestradiol catalyzed by cytochrome P-450
-
Ohe T, Hirobe M, and Mashino T (2000) Novel metabolic pathway of estrone and 17betaestradiol catalyzed by cytochrome P-450. Drug Metab Dispos 28:110-112.
-
(2000)
Drug Metab Dispos
, vol.28
, pp. 110-112
-
-
Ohe, T.1
Hirobe, M.2
Mashino, T.3
-
26
-
-
0025845934
-
Human CYP1A1 gene: Cosegregation of the enzyme inducibility phenotype and an RFLP
-
Petersen DD, McKinney CE, Ikeya K, Smith HH, Bale AE, McBride OW, and Nebert DW (1991) Human CYP1A1 gene: cosegregation of the enzyme inducibility phenotype and an RFLP. Am J Hum Genet 48:720-725.
-
(1991)
Am J Hum Genet
, vol.48
, pp. 720-725
-
-
Petersen, D.D.1
McKinney, C.E.2
Ikeya, K.3
Smith, H.H.4
Bale, A.E.5
McBride, O.W.6
Nebert, D.W.7
-
27
-
-
1642397469
-
Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen
-
Rivera E, Valero V, Francis D, Asnis AG, Schaaf LJ, Duncan B, and Hortobagyi GN (2004) Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen. Clin Cancer Res 10:1943-1948.
-
(2004)
Clin Cancer Res
, vol.10
, pp. 1943-1948
-
-
Rivera, E.1
Valero, V.2
Francis, D.3
Asnis, A.G.4
Schaaf, L.J.5
Duncan, B.6
Hortobagyi, G.N.7
-
28
-
-
77949468258
-
A review of the use of exemestane in early breast cancer
-
Robinson A (2009) A review of the use of exemestane in early breast cancer. Ther Clin Risk Manag 5:91-98.
-
(2009)
Ther Clin Risk Manag
, vol.5
, pp. 91-98
-
-
Robinson, A.1
-
29
-
-
0033811484
-
Allelic variants of human cytochrome P450 1A1 (CYP1A1): Effect of T461N and I462V substitutions on steroid hydroxylase specificity
-
Schwarz D, Kisselev P, Schunck WH, Chernogolov A, Boidol W, Cascorbi I, and Roots I (2000) Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics 10:519-530.
-
(2000)
Pharmacogenetics
, vol.10
, pp. 519-530
-
-
Schwarz, D.1
Kisselev, P.2
Schunck, W.H.3
Chernogolov, A.4
Boidol, W.5
Cascorbi, I.6
Roots, I.7
-
30
-
-
0032414615
-
Molecular genetics of the human cytochrome P450 monooxygenase superfamily
-
Smith G, Stubbins MJ, Harries LW, and Wolf CR (1998) Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 28:1129-1165.
-
(1998)
Xenobiotica
, vol.28
, pp. 1129-1165
-
-
Smith, G.1
Stubbins, M.J.2
Harries, L.W.3
Wolf, C.R.4
-
31
-
-
0038002981
-
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: Implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity
-
Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, and Desta Z (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300.
-
(2003)
J Pharmacol Exp Ther
, vol.306
, pp. 287-300
-
-
Ward, B.A.1
Gorski, J.C.2
Jones, D.R.3
Hall, S.D.4
Flockhart, D.A.5
Desta, Z.6
-
32
-
-
19444376971
-
Drug metabolism and variability among patients in drug response
-
Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221.
-
(2005)
N Engl J Med
, vol.352
, pp. 2211-2221
-
-
Wilkinson, G.R.1
|